AwesomeCapital

Wednesday, May 6, 2020

Veracyte EPS misses by $0.04, beats on revenue

Veracyte (NASDAQ:VCYT): Q1 GAAP EPS of -$0.24 misses by $0.04.

Revenue of $31.12M (+5.4% Y/Y) beats by $0.06M.

https://seekingalpha.com/news/3570531-veracyte-eps-misses-0_04-beats-on-revenue

Quidel beats on revenue

Quidel (OTC:QDEL): Q1 Non-GAAP EPS of $1.22; GAAP EPS of $0.93.

Revenue of $174.65M (+18.0% Y/Y) beats by $14.04M.

Shares +2.33%.

https://seekingalpha.com/news/3570541-quidel-beats-on-revenue

Opko Health Q1 revenues down 5% due to COVID-19 headwinds

OPKO Health (NASDAQ:OPK) Q1 results:

Total revenue: $211.5M (-4.9%); lab services: $170.8M (-4.5%); product sales: $31.1M (+22.9%). Decline in lab services due to COVID-19 disruptions (outweighed the increase from pandemic-related testing).

Net loss: ($59.1M); loss/share: ($0.09).

BioReference Laboratories unit has run 700K COVID-19 tests to date and can handle 35K per day. Capacity will expand to 400K/day within the next two weeks.

Rayaldee prescriptions up 78% from a year ago to ~18,327.

16K 4Kscore tests performed.

Shares down 2% after hours.

OPKO Health EPS in-line, misses on revenue

https://seekingalpha.com/news/3570536-opko-health-q1-revenues-down-5-due-to-covidminus-19-headwinds

Bio-Rad Labs EPS beats by $0.34, beats on revenue

Bio-Rad Labs (NYSE:BIO): Q1 Non-GAAP EPS of $1.91 beats by $0.34; GAAP EPS of $22.72.

Revenue of $571.6M (+3.2% Y/Y) beats by $25.9M.

https://seekingalpha.com/news/3570574-bio-rad-labs-eps-beats-0_34-beats-on-revenue

Qiagen Q1 sales up 7%, increased growth expected this quarter

QIAGEN N.V. (NYSE:QGEN) Q1 results:

Sales: $372.1M (+6.7%).

Molecular diagnostics revenue up 4% to $176M.

Net income: $39.8M (+34.9%); EPS: $0.17 (+30.8%); non-GAAP EPS: $0.34 (+25.9%).

Cash flow ops: $15.9M (-64.4%).

Q2 guidance: Sales growth at least 12%; non-GAAP EPS at least $0.40.

2020 guidance withdrawn.

Qiagen EPS beats by $0.07, beats on revenue

https://seekingalpha.com/news/3570589-qiagen-q1-sales-up-7-increased-growth-expected-this-quarter

Cellular Biomedicine EPS beats by $0.16

Cellular Biomedicine (NASDAQ:CBMG): Q1 GAAP EPS of -$0.60 beats by $0.16.

Cash, equivalents and restricted cash of $21.6M (+40.3% Q/Q)

https://seekingalpha.com/news/3570635-cellular-biomedicine-eps-beats-0_16

MyoKardia EPS misses by $0.11

MyoKardia (NASDAQ:MYOK): Q1 GAAP EPS of -$1.50 misses by $0.11.

Cash, cash equivalents and investments of $360.1M.

https://seekingalpha.com/news/3570660-myokardia-eps-misses-0_11

Subscribe to: Comments (Atom)